Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma
Conditions
Keywords
radiomics, pathomics, breast cancer, machine learning, biomarkers
Brief summary
This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.
Detailed description
The specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of metastasis from primary breast cancer to other distant sites, (3) determine the rates of local recurrence in breast cancer patients, and (4) to determine if there are significant radiomic, pathomic, and clinical markers for recurrence and distant metastasis.
Interventions
DIAGNOSTIC_TESTRadiomic, pathomic, and clinical markers
This is a non-interventional study.
Sponsors
Sunnybrook Health Sciences Centre
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must be men and women age 18+ * Biopsy-confirmed diagnosis of invasive breast cancer; (ER+/-, PR+/-, HER2+/-) * Any state of disease as described by AJCC v7 criteria * Participants must have received and completed neoadjuvant chemotherapy
Exclusion criteria
* Participants who had other primary cancers prior to breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic complete response (pCR) | Up to 60 months | Evaluating the degree of absence of residual cancer cells |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to local breast recurrence | Up to 60 months | Evaluating the time until a recurrence event has occurred in the breast |
| Time to distant metastasis (months) | Up to 60 months | Evaluating onset of distant metastasis |
| Time to death | Up to 60 months | Evaluating time to cancer-related death |
Countries
Canada
Outcome results
None listed